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Type 2 diabetes (T2DM) and its complications constitute a major worldwide public health problem, with high rates of morbidity
and mortality. Biomarkers for predicting the occurrence and development of the disease may therefore offer benefits in terms of
early diagnosis and intervention. This review provides an overview of human studies on circulating biomarkers of oxidative
stress and antioxidant defence systems and discusses their usefulness from a clinical perspective. Most case-control studies
documented an increase in biomarkers of oxidative lipid, protein, and nucleic acid damage in patients with prediabetes and in
those with a diagnosis of T2DM compared to controls, and similar findings were reported in T2DM with micro- and
macrovascular complications compared to those without. The inconsistence of the results regarding antioxidant defence systems
renders difficulty to draw a general conclusion. The clinical relevance of biomarkers of oxidative lipid and protein damage for
T2DM progression is uncertain, but prospective studies suggest that markers of oxidative nucleic acid damage such as 8-
hydroxy-2′-deoxyguanosine and 8-hydroxyguanosine are promising for predicting macrovascular complications of T2DM.
Emerging evidence also points out the relationship between serum PON1 and serum HO1 in T2DM and its complications.
Overall, enhanced oxidative damage represents an underlying mechanism of glucose toxicity in T2DM and its related micro-
and macrovascular complications suggesting that it may be considered as a potential additional target for pharmacotherapy.
Therefore, further studies are needed to understand whether targeting oxidative stress may yield clinical benefits. In this view,
the measurement of oxidative stress biomarkers in clinical trials deserves to be considered as an additional tool to currently used
parameters to facilitate a more individualized treatment of T2DM in terms of drug choice and patient selection.
1. Introduction
Type 2 diabetes (T2DM) and its complications constitute a
major worldwide public health problem, with high rates of
morbidity and mortality [1]. T2DM is strongly associated
with both microvascular (retinopathy, nephropathy, and
neuropathy) and macrovascular complications, including
ischemic heart disease, peripheral vascular disease, and
stroke [2]. Since T2DM often remains undiagnosed due
to the mild or asymptomatic nature of this condition, vas-
cular complications may be already present in the early
phases of the disease and even in the prediabetic stage
[3]. Biomarkers predictive of the occurrence and develop-
ment of T2DM and its complications may therefore offer
benefits in terms of early diagnosis and intervention, thus
slowing down disease progression. Oxidative stress, defined
as an imbalance between the production of reactive oxy-
gen species (ROS) and antioxidant defence systems, has
been often associated with the development of diabetes
and its complications [4–6].
Several biomarkers of oxidative stress are available,
including ROS themselves. However, since ROS are very
reactive and have a short half-life, it is more suitable to esti-
mate oxidative stress by measuring their oxidation target
products, including lipid peroxidation, oxidized proteins,
and oxidative nucleic acid damage [7].
In this review, we will provide an overview of human
studies on circulating biomarkers of ROS-induced
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modifications of lipids, nucleic acids, and proteins as well as
markers of antioxidant defence systems evaluated in the
plasma, serum, or urines of T2DM patients and discuss their
utility in predicting the onset and progression of the disease.
2. Overview on the Mechanisms of Oxidative
Stress Generation and Antioxidant
Defence Systems
ROS including superoxide (O2
·-), hydroxyl radical (OH·),
hydrogen peroxide (H2O2), and singlet oxygen (
1O2
-) are
generated during normal aerobic metabolism, and low levels
are necessary for several basic biological processes including
cellular proliferation and differentiation [8, 9]. Many cell
types can produce ROS including macrophages, neutrophils,
and endothelial and epithelial cells; however, excessive pro-
duction can induce oxidative stress with detrimental effects
on cellular components such as nucleic acids, proteins, and
lipids [10–13] (Figure 1).
2.1. Sources of Oxidative Stress. Mitochondria have a major
contribution to ROS production, particularly O2
·-, a side
product of electron transport during oxidative phosphoryla-
tion. H2O2 is produced in vivo by many reactions, easily
crosses cellular membranes and, receiving one or more
electrons from iron or copper, generates OH·, the most
abundant and damaging radical in the body, although very
short-lived [14].
The two major ROS-generating enzymatic systems are
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase (NOX family) and xanthine oxidase (XO).
Although the expression of NOX was initially thought to
be confined to neutrophils and macrophages, it is also
present in endothelial cells, cardiomyocytes, hematopoietic
stem cells, and platelets [15]. During purine degradation,
XO catalyses electron transfer to oxygen molecules which
generates H2O2 and O2
·- species [16]. Although with
minor activity, other sources of ROS include myeloperox-
idase (MPO), which contributes to the progression of ath-
erosclerotic plaque by oxidizing LDL [15], lipoxygenase
(LOX), cyclooxygenase (COX), and monoamine oxidases
(MAO-A and MAO-B) [17]. Endothelial nitric oxide syn-
thase (eNOS) normally produces the potent vasodilator
NO· by catalysing the conversion of L-arginine to L-citrul-
line, and in this process, the presence of cofactor tetrahy-
drobiopterin (BH4) is essential [18]. However, in the
absence of either L-arginine or BH4, eNOS can produce
O2
·-, in a phenomenon referred as “eNOS uncoupling”
associated with increased ROS production in aging and
cardiovascular diseases [18] (Figure 1).
2.2. Enzymatic and Nonenzymatic Antioxidant Defence
Systems. The enzymatic and nonenzymatic antioxidant
defence systems regulate ROS formation and protect biolog-
ical systems from ROS-induced oxidative damage. Among
the antioxidant enzymes, superoxide dismutase (SOD), cata-
lase (CAT), glutathione peroxidase (GPx), and paraoxonase
(PON) are the most studied. The nonenzymatic sources of
antioxidants include ascorbic acid, tocopherol, uric acid,
and glutathione (GSH); the latter acts as a ROS scavenger,
and it is the substrate of the GPx enzyme; during this reac-
tion, GSH is oxidized to GSSG, and through glutathione
reductase (GR) activity, it is reconverted to GSH with
NADPH as cofactor. SOD catalyses the conversion of O2
·-
to H2O2 that can be converted to H2O through the CAT
enzyme [19] or through GSH by GPx [20]. PONs are a family
of three enzymes able to hydrolyse aryl esters, lactones, and
organophosphates, synthesized mainly in the liver and
secreted into the plasma. PON1 is involved in lipid metabo-
lism since it is a key functional constituent of HDL and pro-
tects low-density lipoprotein (LDL) from oxidation [21].
Among antioxidant protective systems, Nrf2 (nuclear
factor-E2-related factor 2) is a transcription factor capable
to induce a set of antioxidant and detoxification enzymes
[22]. Under stressful conditions or in the presence of Nrf2-
activating compounds, Nrf2 translocates to the nucleus to
induce the expression of its target genes such as heme oxyge-
nases (HOs), a family of enzymes that catalyses the degrada-
tion of heme producing biliverdin, ferrous iron, and carbon
monoxide [23]. HO1 is localized in the brain, kidney, heart,
liver, and vascular smooth muscle cells, and its induction is
important in initiating protective mechanisms in response
to stressful stimuli [24] (Figure 1).
3. Association between Oxidative Damage and
Antioxidant Defence Systems with the
Development of T2DM and Its Complications
Chronic hyperglycaemia leads to the generation of oxidative
stress in pancreatic β-cells which are particularly vulnerable
to the damaging effects of excessive ROS production because
of their lower abundance of antioxidant defence enzymes,
compared to other tissues [25]. Due to their ability to directly
damage and oxidize DNA, protein and lipid ROS lead to β-
cell dysfunction and death. In addition to macromolecular
damage, ROS can activate a number of cellular stress-
sensitive pathways that have been linked to insulin resistance
and decreased insulin secretion [6]. The development of not
only β-cell dysfunction and insulin resistance but also the
late complications of diabetes has been linked to
hyperglycaemia-induced oxidative stress through the four
main molecular mechanisms: the polyol pathway, advanced
glycation end product (AGE) formation, the protein kinase
C- (PKC-) diacylglycerol (DAG), and the hexosamine path-
ways [26, 27]. Moreover, oxidative stress originates from
the oxidative biochemistry of glucose itself, which undergoes
autoxidation generating ROS which in turn can directly oxi-
dize and damage DNA, RNA, proteins, and lipids activating a
number of cellular stress-sensitive pathways that cause cellu-
lar damage in the endothelial cells of large and small vessels
as well as in the myocardium engaging vicious cycles that fur-
ther exacerbate organ dysfunction [5]. In fact, oxidative stress
is associated with increased expression of proinflammatory
cytokines, growth factors, procoagulant factors, adhesion
molecules, and decreased nitric oxide release, all pathophys-
iological events leading to endothelial dysfunction and
micro- and macrovascular diseases [28, 29] (Figure 2).
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Figure 1: Mechanisms of hyperglycaemia-induced oxidative damage to nucleic acids, lipids and proteins. All abbreviations are spelled out in
the text.
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Figure 2: Schematic diagram summarizing the damaging effects of oxidative stress-induced damage to nucleic acids, lipids, and proteins
leading to the development and progression of diabetic complications including cardiomyopathy and cardiovascular diseases, retinopathy,
nephropathy, and neuropathy. All abbreviations are spelled out in the text.
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3.1. AGEs in the Development of T2DM and Its
Complications. In T2DM, the presence of persistently ele-
vated glucose levels increases the frequency of AGEs, a het-
erogeneous group of compounds derived from the
nonenzymatic glycation of proteins, lipids, and nucleic acids
through the Maillard reaction [30]. Glycation, in addition to
glycoxidation, can cause structural and functional impair-
ments of plasma proteins in particular albumin [31], and it
is involved in the pathophysiological mechanism of vascular
diseases in T2DM [32]. By binding to their cell surface recep-
tor (RAGE) on macrophages and endothelial cells, AGEs
trigger a cascade of ROS generation and activation of proin-
flammatory pathways and profibrotic factors such as nuclear
factor-κB (NF-κB), vascular cell adhesion molecule-1
(VCAM-1), intercellular adhesion molecule-1 (ICAM-1),
plasminogen activator inhibitor-1 (PAI-1), and monocyte
chemoattractant protein-1 (MCP-1) involved in the progres-
sion of atherosclerosis and vascular pathology [33].
Immunohistochemical studies have shown that AGEs
accumulate in the mesangium and glomerular capillary
wall [34] and in the peripheral nerves of diabetic patients
[35] suggesting their role in the pathogenesis of micro-
vascular complications.
3.2. Lipid Peroxidation in the Development of T2DM and Its
Complications. Bioactive products of lipid peroxidation
induce disturbances in membrane organization, functional
loss, and modifications of enzymes, carriers, and cytoskeletal
and mitochondrial proteins as well as DNA bases leading to
cell death or inducing alterations in the biochemical proper-
ties of these biomolecules [36].
3.3. Protein Oxidation in the Development of T2DM and Its
Complications. The oxidative modification of proteins has
been also linked to the pathological conditions of the vascular
system: the most well-studied proteins are carbonylated pro-
teins which accumulate as nonfunctional protein aggregates
that can become cytotoxic [7].
Advanced oxidation protein products (AOPPs) are
dityrosine-containing and crosslinking proteins found in
atherosclerotic lesions and promote vascular inflammation,
monocyte activation, and endothelial dysfunction through
the overexpression of adhesion molecules such as ICAM-1
and VCAM-1 [37, 38].
3.4. Nucleic Acid Oxidative Damage in the Development of
T2DM and Its Complications. Oxidative stress also leads to
DNA damage and accumulation of 8-hydroxy-2′-deoxy-
guanosine (8-OHdG) in atherosclerotic plaques [39] as well
as in the kidney of diabetic rats [40]. Another possible mech-
anism by which DNA oxidation could be involved in the
development of vasculopathy and atherosclerosis is the
induction of cell senescence via telomeric or nontelomeric
DNA damage [41]. RNA also undergoes significant oxidation
forming 8-hydroxyguanosine (8-oxoGuo), which leads to
ribosomal dysfunction, formation of nonfunctional or trun-
cated proteins, and reduced levels of functional proteins
[42]. RNA and DNA oxidation appears in the early stage of
diabetic nephropathy [43], and the levels of oxidized purines
and pyrimidines are elevated in the iris tissues of diabetic
patients with glaucoma [44].
3.5. Antioxidant Defence System in the Development of T2DM
and Its Complications. A defective antioxidant defence sys-
tem has been also associated with diabetes and its complica-
tions: because of their low levels of antioxidants, β-cells are
particularly susceptible to ROS, and hyperglycaemia itself
depletes GSH by causing nonenzymatic glycation of GR
and GPx, with inhibition of their reductive enzymatic activity
[45]. Decreased SOD activity has been implicated in the
pathogenesis of retinopathy in diabetes, and its overexpres-
sion prevented hyperglycaemia-associated production of
ROS, activation of PKC, and AGE formation [46, 47]. There
is also evidence that HO1 can protect against vascular dam-
age and atherogenesis [48]: HO1 is upregulated in macro-
phages during the development of inflammation in
atherosclerosis, with a consequently decreased expression of
VCAM-1 and proinflammatory cytokines [49]; HO1 overex-
pression inhibits atherosclerosis by reducing ox-LDL both in
the plasma and in the artery wall and reduces glomerular
injury and apoptosis in diabetic rats [50–52]. PON1 also
has an atheroprotective function, and its reduced activity in
T2DM seems to be due to its nonenzymatic glycation [53].
4. Biomarkers of Lipid Peroxidation
Lipid peroxidation is the free radical oxidation of polyun-
saturated fatty acids (PUFAs) such as linoleic acid or ara-
chidonic acid, and it is capable of extensive tissue damage
[54]. ROS-induced peroxidation of membrane lipids, in
fact, alters the structure and the fluidity of biological
membranes, which ultimately affect their function.
Among the most frequently studied markers of lipid per-
oxidation are isoprostanes such as 8-iso-prostaglandin
F2α (8-iso-PGF2α), malondialdehyde (MDA), thiobarbitu-
ric acid reactive substances (TBARS), and hydroxynone-
nal (HNE) [55]. MDA is a highly reactive nucleophilic
agent generated by both lipid peroxidation and as a by-
product of prostaglandin and thromboxane synthesis that
can attack macromolecules, including amino acid or sulf-
hydryl moiety of proteins leading to alterations in their
functions [56]. HNE is a major toxic aldehyde generated
by ROS attack to ω-6 polyunsaturated fatty acids and
reacts with proteins forming advanced lipoxidation end
products. Both HNE and MDA adducts were detected
in atherosclerotic lesions [7].
Another lipid peroxidation product with prostaglandin-
like structure, produced primarily from esterified arachi-
donic acid by nonenzymatic reactions catalysed by free
radicals, is 8-iso-PGF2α [55] that can contribute to platelet
activation [36].
4.1. Lipid Peroxidation in the Prediabetic Stage (Retrospective
Studies). In prediabetic patients, urinary 8-iso-PGF2α were
higher than in healthy volunteers but negatively correlated
with HbA1c [57]. Similarly, the levels of 8-iso-PGF2α and
MDA were higher in the plasma of prediabetics compared
to healthy subjects but lower than in the T2DM patients
4 Oxidative Medicine and Cellular Longevity
[58]. However, other studies reported no differences in uri-
nary isoprostanes and TBARS between prediabetes and con-
trols [59, 60] (Table 1).
4.2. Lipid Peroxidation in T2DM with and without
Complications (Retrospective Studies). One of the most con-
sistent findings on lipid peroxidation markers in T2DM
patients with and without complications was a significant
increase in TBARS or MDA compared to healthy controls
[61] (Table 1) and in T2DM patients with micro- and macro-
vascular complications as compared to those without [62–
64] (Table 2). MDA was also significantly increased in
T2DM both with and without complications and performed
better than ischemia-modified albumin (IMA), but it was of
minor value compared to glycated haemoglobin (HbA1c)
measurement in the evaluation of diabetes progression [65]
(Table 2). T2DM patients with poor glycaemic control had
significantly higher levels of MDA, when compared with
the controlled T2DM patients and the control group [66,
67] (Tables 1 and 2). We also previously reported that circu-
lating MDA was increased in poorly controlled T2DM with
and without complications [63], and this effect was more
pronounced in females [68]; however, other authors found
no differences in MDA and isoprostanes between female
T2DM patients with high or low HbA1c [69] (Table 2).
Significantly higher levels of MDA in T2DM with ische-
mic heart disease were found in the study of Djindjic et al.
[70] and in T2DM with chronic kidney disease as compared
to patients without complications and healthy controls [71]
whereas other studies reported no differences in patients with
or without nephropathy [72, 73] (Table 2).
5. Advanced Glycation End Products (AGEs)
AGEs are a complex group of compounds formed via a non-
enzymatic reaction between reducing sugars and amine resi-
dues on proteins, lipids, or nucleic acids. The major AGEs
in vivo appear to be formed from highly reactive intermedi-
ate carbonyl groups, including 3-deoxyglucosone, glyoxal,
and methylglyoxal [74]. Some of the best chemically charac-
terized AGEs in humans include pentosidine and N(carbox-
ymethyl)lysine [75].
5.1. AGEs in T2DM with and without Complications
(Retrospective Studies). Plasma AGE levels were significantly
higher in T2DM compared to controls and in diabetics with
vascular complications compared to those without [64, 76,
77] (Table 2). On the contrary, Chou and Tseng [73] found
no differences in AGE levels in T2DM with mild or severe
nephropathy and those without (Table 2).
5.2. AGEs in Prospective Clinical Studies. Baseline plasma
levels of AGEs were associated with several subclinical ath-
erosclerosis parameters over 10 years of follow-up in patients
with long-standing T2DM [78] and predicted the incidence
of cardiovascular disease [79]. However, in a recent large pro-
spective clinical trial, AGEs were not associated with the risk
of major adverse cardiovascular disease in multivariate anal-
ysis [80] and were not associated with the risk of major lower
extremity artery disease in T2DM [81] (Table 3).
6. Biomarkers of Protein Oxidation
Carbonyl derivatives (aldehydes and ketones) are formed by
direct oxidation of amino acid residues by ROS or nonoxida-
tive reactions with carbonyl-containing oxidized lipids [82].
Carbonyl levels are the most widely used marker of oxidative
protein damage, because of the relative early formation and
stability [83]. Advanced oxidation protein products (AOPPs)
are formed in the reaction of chlorinated oxidants, such as
chloramines and hypochlorous acid with plasma proteins,
mostly albumin [82].
6.1. Protein Carbonyl and AOPPs in T2DM with and without
Complications (Retrospective Studies). Protein carbonyl and
AOPPs were significantly higher in T2DM patients in com-
parison to healthy volunteers [62, 65, 76, 84] and were also
increased in those with micro- or macrovascular complica-
tions compared to T2DM without complications [62, 64,
65, 76, 84] (Tables 1 and 2). A progressive increase in AOPP
plasma levels in the course of albuminuria was also noted,
and AOPP was better than IMA in distinguishing patients
with micro- and macroalbuminuria [85] (Table 2). Plasma
AOPP concentrations were an independent risk factor for
endothelial dysfunction in individuals at an early stage of dia-
betes [86] (Table 2). Increased protein carbonyls in red blood
cells were also observed in diabetic retinopathy [87] but not
in T2DM with stable ischemic heart disease [70] (Table 2).
Carbonyl residues in poorly controlled T2DMwith and with-
out complications were higher compared to well controlled
without complications [63] and were positively associated
with the cardiovascular risk score [88] (Table 2).
6.2. Protein Carbonyl and AOPPs in Prospective Clinical
Studies. A recent large prospective clinical trial indicated that
both carbonyls and AOPP were not associated with the risk
of major adverse cardiovascular events [80]; similarly, no
association between the baseline levels of protein carbonyls
and lower-extremity artery disease was observed by Nativel
et al. [81] (Table 3).
7. Biomarkers of Oxidative DNA and
RNA Damage
7.1. 8-OHdG and 8-oxoGuo in Prediabetes and in T2DM
(Retrospective Studies). A well-known biomarker of oxidative
DNA damage is 8-OHdG [89], and consistent evidence from
observational studies showed increased urinary 8-OHdG
levels in both prediabetes and T2DM compared to controls
[57, 59, 90] (Tables 1 and 2). Urinary levels of 8-OHdG
and of the RNA oxidation marker, 8-oxo-7,8-dihydroguano-
sine (8-oxoGuo), were elevated in T2DM patients with and
without complications compared with age-matched healthy
controls [91]. Jelinek et al. [92] also identified 8-OHdG as a
HbA1c comarker for T2DM diagnosis.
7.2. 8-OHdG and 8-oxoGuo in T2DM with and without
Complications (Retrospective Studies). Patients with compli-
cations, especially macrovascular complications, exhibited
higher levels of 8-OHdG than those without complications
[91] (Table 2). Chou and Tseng [73] reported increased
5Oxidative Medicine and Cellular Longevity
Table 1: Selected clinical retrospective studies on circulating oxidative stress markers in T2DM and prediabetes. All the studies included in
this table were categorized under the class of evidence C, retrospective studies.
Disease and
population
Sample Markers Observation
Information on medication or
supplements
Reference
Prediabetics
(N = 47)
T2DM
(N = 43)
Controls
(N = 37)
Urine
8-OHdG
8-iso-PGF2α
↑ 8-iso-PGF2α and 8-OHdG in prediabetes
compared to controls
↑ 8-OHdG in T2DM patients compared to
controls
No medication
No special diet
No supplements
[57]
Prediabetics
(N = 176)
Controls
(N = 252)
Urine
Erythrocytes
8-iso-PGF2α
8-OHdG
GSH/GSSG
No differences in 8-iso-PGF2α
↑ 8-OHdG in prediabetes group compared to
control
↓ GSH/GSSG in prediabetes compared to
control
Antihypertensive drugs:
Prediabetes (35.8%)
Controls (5.2%)
Statins and anticoagulants:
Controls (<4%)
Prediabetes (<16%)
[59]
Prediabetics
(N = 49)
T2DM
(N = 30)
Controls
(N = 30)
Plasma
8-iso-PGF2α
MDA
TAOC
SOD
↑ 8-iso-PGF2α and MDA in prediabetes and
T2DM compared to controls
↑ 8-iso-PGF2α in T2DM compared to
prediabetes
↓ TAOC in T2DM compared to controls and
prediabetes
↓ SOD in prediabetes compared to controls
No differences in TAOC between prediabetes
and controls
↓ SOD in T2DM compared to controls and
prediabetes
No use of medication that affects
glucose metabolism within 6
months
[58]
Prediabetics
(N = 111)
T2DM
(N = 186)
Controls
(N = 259)
Plasma and
erythrocyte
Nrf2
MDA
TAS
GPx
SOD
GSH
↓ TAS and GSH in controlled and
uncontrolled T2DM compared to controls
and prediabetes
↓ Nrf2 in prediabetes and in uncontrolled
T2DM compared to controls
↑ MDA in uncontrolled T2DM compared to
controls and prediabetes and in controlled
T2DM compared to controls
↑ GPx in uncontrolled T2DM compared to
prediabetes
↑ SOD in controlled and uncontrolled T2DM
compared to prediabetes and controls
Not provided [67]
Prediabetics
(N = 9)
T2DM
(N = 55)
Controls
(N = 29)
Ethnicity:
whites,
blacks,
Brazilians
Plasma and
erythrocyte
SOD
CAT
GPx
TBARS
No differences in TBARS, SOD, GPx, and
CAT between prediabetes and controls
↑ SOD and TBARS in T2DM compared to
controls and prediabetes
Antihypertensive drugs: 76.4% of
T2DM, 66.7% of the pre-DM, and
37.9% of the controls
Among T2DM: 92.7%
sulphonylurea and/or biguanide
[60]
T2DM
(N = 215)
Controls
(N = 37)
Serum
SOD
TBARS
GSH
↓ SOD and GSH in T2DM compared with
controls
↑ TBARS in T2DM compared with controls
Not provided [61]
T2DM
(N = 39)
Controls
(N = 18)
Plasma FRAP
↓ FRAP lower in T2DM with poor glycaemic
control than controls
T2DM treated with metformin
and glibenclamide in
combination with other
[99]
T2DM
(N = 31) Plasma
Protein
carbonyl
AOPP
↑ protein carbonyl content and AOPPs in
T2DM in comparison to healthy volunteers
Not provided [84]
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plasma-8-OHdG levels in diabetic patients with micro- and
macroalbuminuria compared to normoalbuminuric patients.
Similarly, urinary 8-OHdG levels were significantly higher in
T2DM with microvascular complications when compared to
those without and better discriminate microvascular compli-
cations compared with urinary albumin [93]. On the con-
trary, Serdar et al. [90] found no differences in patients
with and without nephropathy (Table 2).
7.3. 8-OHdG and 8-oxoGuo in Prospective Clinical Studies.
Urinary excretion of 8-oxoGuo measured shortly after the
diagnosis of T2DM predicted long-term mortality indepen-
dent of conventional risk factors [94] (Table 3). In the
ADVANCE prospective trial, increased levels of 8-OHdG
were independently associated with all-cause and cardiovas-
cular mortality in 3766 T2DM [95]. In a recent prospective
cohort study involving 1863 patients with T2DM, 8-
oxoGuo was associated with all-cause mortality and cardio-
vascular death after multiple regression analysis [96]. More-
over, recent findings suggest that urinary 8-oxoGuo
provides additional information about risk to that obtained
from urinary albumin and that the combined use of 8-
oxoGuo and urinary albumin could be useful for a better
identification of patients at risk of CVD and death over a
period of 19 years of follow-up [97] (Table 3).
8. Biomarkers of Antioxidant Defence Systems
8.1. Nonenzymatic Antioxidant Defence Systems
(Retrospective Studies). Reduced levels of GSH and Nrf2
[59, 67] and no change in total antioxidant status [58]
were reported in the prediabetic stage compared to con-
trols. Total antioxidant status was reduced in T2DM
patients compared to controls and prediabetic patients in
[58, 67, 84], increased in T2DM patients compared to
controls in [98], and unchanged in [99] (Table 1). We
previously reported that FRAP levels were significantly
lower only in diabetics with poor glycaemic control, while
patients with good glycaemic control had FRAP values
similar to controls [100]; on the contrary, total antioxidant
status was reduced in T2DM compared to controls, inde-
pendently of glycaemic control in [67] (Table 1).
Table 1: Continued.
Disease and
population
Sample Markers Observation
Information on medication or
supplements
Reference
Controls
(N = 31)
Radical
scavenging
capacity of
plasma
↓ Radical scavenging capacity of plasma in
T2DM than controls
T2DM
(N = 80)
Controls
(N = 79)
Plasma
FRAP
GSH
GR
GPx
↑ FRAP and GR in T2DM compared to
controls
↓GPx activity in T2DM compared to controls
Not provided [98]
T2DM
(N = 115)
Controls
(N = 32)
Plasma
GSH
GPx
TAS
↓ GSH, GPx in T2DM compared to controls
No differences in TAS
No use of vitamins, minerals, or
other supplements
[100]
T2DM
(N = 420)
Controls
(N = 429)
Plasma HO1 ↑ HO1 in T2DM compared to controls Not provided [110]
T2DM
(N = 30)
Controls
(N = 20)
Ethnicity:
Indian
Serum PON1 ↑ PON1 in controls compared to T2DM Not provided [102]
T2DM
(N = 90)
Controls
(N = 90)
Serum PON1 ↑ PON1 in controls compared to T2DM Not provided [103]
T2DM
(N = 145)
Controls
(N = 574)
Serum PON1 ↑ PON1 in controls compared to T2DM
10 controls and 15% of T2DM
were on active lipid-lowering
treatment
[104]
8-iso-PGF2α: 8-iso- prostaglandin F2α ; 8-OHdG: 8-hydroxy-2′-deoxyguanosine; AGEs: advanced glycation end products; AOPP: advanced oxidation protein
products; CAT: catalase; FRAP: ferric reducing ability of plasma; GSH: reduced glutathione; GSSG: oxidized glutathione; GPx: glutathione peroxidase; GR:
glutathione reductase; HNE: 4- hydroxy-2-nonenal; HO1: heme oxygenase; MDA: malondialdehyde; Nrf2: nuclear factor erythroid 2; PON1: paraoxonase 1;
SOD: superoxide dismutase; TBARS: thiobarbituric acid reactive substances; TAS: total antioxidant status.
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Table 2: Selected clinical retrospective studies on circulating oxidative stress markers in T2DM with and without complications. All the
studies included in this table were categorized under the class of evidence C, retrospective studies.
Disease and population Sample Markers Observation
Information on medication or
supplements
Reference
T2DM (N = 85)
T2DM with micro- and
macrovascular
complications (N = 75)
Controls (N = 60)
Plasma and
erythrocytes
Protein
carbonyl
TBARS
FRAP
GSH
CAT
↑ protein carbonyls in T2DM and
T2DM with complications
compared to controls and in T2DM
with complications compared to
T2DM without
↑ TBARS higher in T2DM and
T2DM with complications
compared to controls and in T2DM
with complications compared to
T2DM without
↓ FRAP, GSH, and CAT in T2DM
and T2DM with complications
compared to controls
↓ GSH in T2DM and T2DM with
complications compared to controls
and in T2DM with complications
compared to T2DM without
No antioxidants [62]
T2DM with
complications (N = 50)
T2DM without
complications (N = 50)
Controls (N = 50)
Plasma
MDA
AOPP
↑ MDA and AOPP in T2DM
compared to controls
↑ MDA and AOPP in T2DM with
complications compared to T2DM
without complications
4% of T2DM without complications
and 42% of T2DM with
complications were on insulin
treatment
96% of T2DM without
complications and 58% of T2DM
with complications were on oral
hypoglycaemic drug treatment
[65]
T2DM with poor
glycaemic control
without complications
(N = 52)
T2DM with poor
glycaemic control with
complications (N = 37)
Plasma
MDA
Protein
carbonyl
FRAP
SOD
↑ SOD and FRAP in patients with
complications
↑ MDA in females with
complications compared to those
without
No differences in carbonyl residues
between males and females
Multiregression analysis:
Statin treatment was associated with
SOD in females
Metformin treatment was inversely
associated with MDA
[68]
T2DM with good
glycaemic control
without complications
(N = 15)
T2DM with poor
glycaemic control
without complications
(N = 28)
T2DM with poor
glycaemic control with
micro- and
macrovascular
complications (N = 29)
Plasma
MDA
Protein
carbonyl
FRAP
SOD
↑ MDA and carbonyl residues in
T2DM with poor glycaemic control
with and without complications
compared to poorly controlled
↓ FRAP in poorly controlled
without complications compared to
well controlled without
complications
↑ SOD in T2DM with poor
glycaemic control with
complications compared to well
controlled
Medications (nonexclusive):
sulphonylureas (n = 12), biguanides
(n = 46), insulin (n = 30),
thiazolidinediones (n = 2),
meglitinides (n = 4), statins (n = 31),
and antihypertensive drugs (n = 58)
Multiregression analysis indicated
no confounding effect of statin or
metformin
[63]
T2DM with
nephropathy (N = 50)
T2DM without
nephropathy (N = 50)
Controls (N = 50)
Plasma
MDA
FRAP
GSH
↑MDA in T2DM with nephropathy
compared to those without and
controls
↓ FRAP and GSH in T2DM with
and without nephropathy compared
to controls
Patients on inhibitors of the renin-
angiotensin-aldosterone system,
aspirin, and vitamin D analogues
were advised to stop these drugs for
one week before inclusion in the
study
[71]
T2DM with
nephropathy (N = 32)
T2DM without
nephropathy (N = 20)
Controls (N = 20)
Urine 8-OHdG
↑ 8-OHdG in T2DM with and
without nephropathy compared to
controls
No differences between T2DM with
and without nephropathy
Not provided [90]
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Table 2: Continued.
Disease and population Sample Markers Observation
Information on medication or
supplements
Reference
T2DM patients with
good glycaemic control
(N = 27)
T2DM patients with
poor glycaemic control
(N = 36)
Controls (N = 16)
Serum MDA
↑ MDA in T2DM with poor
glycaemic control vs. good
glycaemic control and healthy
volunteers
No antioxidants supplementation in
the previous two months
[66]
T2DM female patients
with good glycaemic
control (N = 74)
T2DM female patients
with poor glycaemic
control (N = 72)
Serum,
plasma,
PBMC
MDA
F2-
isoprostanes
FRAP
GSH/GSSG
SOD
CAT
GPx
No differences
Similar distribution of metformin,
insulin, and other antidiabetic
medications in the two groups
[69]
T2DM without
nephropathy (N = 22)
T2DM with mild
nephropathy (N = 22)
T2DM with severe
nephropathy (N = 15)
Plasma and
RBC
AGEs
MDA
8-OHdG
Vitamin C
TAS
GSH
GPx
CAT
SOD
↑ 8-OHdG in T2DM with micro-
and macroalbuminuria compared
to normoalbuminuric patients
↓ vitamin C in T2DM
with micro- and macroalbuminuria
compared to normoalbuminuric
patients
No differences in AGE, MDA, TAS,
GSH, GPx, CAT, and SOD
Distributions were comparable in
the three groups for aspirin and
drugs for diabetes control (four
kinds of medications)
A lower percentage of T2DM
without nephropathy used insulin
and antihyperlipidemic drugs than
T2DM with severe nephropathy
A higher percentage of T2DM with
mild nephropathy used metformin
than the other two groups
[73]
T2DM with
complications
(N = 267)
T2DM without
complications
(N = 366)
Controls (N = 683)
Urine
8-OHdG
8-oxoGuo
↑ 8-OHdG and
8-oxoGuo in T2DM compared to
controls
↑ 8-oxoGuo in T2DM with
macrovascular complications
compared to those without
complications
Not provided [91]
T2DM with
microvascular
complications (N = 30)
T2DM without
complications (N = 24)
Controls (N = 22)
Urine 8-OHdG
↑ 8-OHdG in T2DM with
microvascular complications than
those without complications
Not provided [93]
T2DM with
microvascular
complications (N = 25)
T2DM with
macrovascular
complications (N = 25)
T2DM without
complications (N = 25)
Serum
AGEs
Protein
carbonyl
MDA
AOPP
↑ MDA, protein carbonyl, AOPP,
and AGE in T2DM with micro- and
macrovascular complications
compared to T2DM without
complications
Not provided [64]
T2DM with micro-and
macrovascular
complications (N = 55)
T2DM without
complications (N = 26)
Controls (N = 20)
Plasma
AGEs
AOPPs
↑ AGE and AOPPs in T2DM
compared to controls
↑AGE in T2DMwith complications
compared to those without
No antioxidant supplements
Lipid- or triglyceride-lowering
drugs: 62% of T2DM without
complications and 73% with
complications
[76]
T2DM (N = 153)
Controls (N = 65) Plasma AOPP
↑AOPP in T2DMwith albuminuria
compared to those without
AOPP was better than IMA in
Not provided [85]
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Table 2: Continued.
Disease and population Sample Markers Observation
Information on medication or
supplements
Reference
distinguishing patients with micro-
and macroalbuminuria
Newly diagnosed
T2DM without
albuminuria (N = 112)
Newly diagnosed
T2DM with
albuminuria (N = 35)
Controls (N = 49)
Plasma AOPP
↑AOPP in T2DMwith albuminuria
compared to those without and to
controls
No hypoglycaemic or
antihypertensive drugs, lipid-
lowering agents, or antioxidants
(vitamin C, vitamin E, or lipoic acid)
[86]
Poorly controlled
T2DM with vascular
complication (N = 44)
Poorly controlled
T2DMwithout vascular
complication (N = 44)
Controls (N = 31)
Plasma AGE
↑AGE in T2DMwith complications
compared to those without
Not provided [77]
T2DM with
nephropathy (N = 30)
T2DM without
nephropathy (N = 34)
Controls (N = 20)
Serum and
erythrocytes
MDA
SOD
↑ MDA in T2DM compared to
controls
No changes in MDA and SOD in
T2DM with and without
nephropathy
Distributions were comparable in
the groups with and without
nephropathy for antihypertensives,
statins, metformin, sulfonylureas,
and insulin
[72]
T2DM with stable
ischemic heart disease
(N = 30)
T2DM without stable
ischemic heart disease
(N = 30)
Plasma and
serum
Protein
carbonyl
MDA
↑ MDA in T2DM with stable
ischemic heart disease
No differences in protein carbonyl
No antioxidants
Distributions were comparable in
the groups with and without
ischemic heart disease for Ca
channel blockers, beta blockers,
ACE inhibitors/ARB, statins, and
acetylsalicylic acid
[70]
T2DM with
retinopathy (N = 45)
T2DM without
retinopathy (N = 19)
Controls (N = 20)
Red blood
cells
Protein
carbonyl
↑ protein carbonyl in T2DM with
retinopathy compared to those
without and to controls
No vitamin E or C supplementation [87]
T2DM with
normoalbuminuria
(N = 28)
T2DM with
microalbuminuria
(N = 28)
T2DM with
macroalbuminuria
(N = 28)
Controls (N = 28)
Urine HO1
↑ HO1/creatinine in T2DM with
microalbuminuria and
macroalbuminuria compared to
those with normoalbuminuria and
control
↑ HO1/creatinine in T2DM with
normoalbuminuria than controls
Not provided [111]
T2DM with
retinopathy (N = 25)
T2DM without
retinopathy (N = 29)
Healthy control
(N = 24)
Serum PON1
↑ PON1 in controls compared to
T2DM
↑ PON1 in T2DM without
retinopathy compared to T2DM
with retinopathy
No patient under lipid-lowering
therapy
No patient was taking vitamin or
mineral supplements or food
fortified with vitamins
[105]
T2DM with
macrovascular
complications
(N = 130)
T2DM without
complications
(N = 135)
Serum
PON1
AGEs
↑ PON1 in controls compared to
T2DM
↑ PON1 in T2DM without
complications compared to T2DM
with macrovascular complications
↑ AGE in T2DM compared to
controls
No antioxidants
Distribution of antihypertensive
and lipid-lowering drugs not
provided
[106]
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Reduced GSH [67] was observed in T2DMwith good and
poor glycaemic control compared to controls [61, 67, 99],
whereas Nrf2 was reduced only in T2DM with poor glycae-
mic control [67] (Table 1). Grindel et al. [69] found no differ-
ences in GSH and FRAP between T2DM female patients with
and without good glycaemic control. Comparing T2DM
patient with complication to those without, decreased GSH
and FRAP [62, 71] and vitamin C [73] increase in FRAP
levels [68], and no differences in GSH and total antioxidant
status were reported [73] (Table 2). Recently, in a large pro-
spective clinical trial, the total antioxidant capacity of plasma
was not associated with the risk of major cardiovascular
events [80] (Table 3).
8.2. Enzymatic Antioxidant Defence Systems (Retrospective
and Prospective Studies). Regarding antioxidant enzymatic
defence systems, SOD activity was reduced [58] or
unchanged [67, 70] in prediabetes compared to controls
and either increased [60, 67] or decreased [58, 61] in
T2DM compared to controls. No differences in CAT and
GPx activity were observed between prediabetes and control
in [60] (Table 1). GPx was increased in uncontrolled T2DM
compared to prediabetes [67] and decreased compared to
controls [98, 99] (Table 1).
Inconsistent results on SOD, CAT, and GPx were also
found when T2DM patients with complications were com-
pared to those without complications [62, 63, 68, 69, 72,
73] (Table 2). Regarding the protective antioxidant defence
of GPx, González de Vega et al. [101] found the presence of
glycated GPx in sera from diabetic patients, with lower GPx
activity than that measured in healthy individuals, and this
reduction was greater in patients with higher HbA1c.
PON1 levels decreased in T2DM patients compared to
controls and correlated to the duration of diabetes [102–
106] (Table 1). PON1 was reduced in T2DM with retinopa-
thy and macrovascular disease compared to those without
[105, 106] and predicted cardiovascular events in T2DM
[107] (Table 3). Lower PON1 activity was associated with
an increased risk of developing T2DM in a longitudinal study
with a 20-year follow-up [108]; on the contrary, in the PRE-
VEND prospective study involving 5947 participants, no
association was found [109] (Table 3). Plasma HO1 concen-
trations were significantly increased in new-T2DM patients
compared to controls and correlated with plasma glucose
levels [110] (Table 1); increased urine HO1 levels were
detected in T2DM before the onset of significant albuminuria
and were associated with renal derangement in patients with
established diabetic nephropathy [111] (Table 2).
9. Discussion
Several oxidative stress biomarkers in the form of lipid, pro-
tein, and nucleic acid oxidation products have been studied
in T2DM patients, while fewer data in the prediabetic stage
are currently available. In the majority of the studies, urinary
and plasma levels of 8-iso-PGF2α and urinary levels of 8-
OHdG were elevated in the prediabetic stage representing
potential early disease markers in patients at risk for T2DM
which may also enable therapeutic interventions from the
early stages of diabetes where cardiovascular risk is already
increased. Similarly, when oxidative stress biomarkers were
evaluated in patients with clinical diagnosis of T2DM, the
most consistentfindingacrossmanyof these studieswas a signif-
icant increase in the plasma levels of TBARS,MDA, AGEs, pro-
tein carbonyls, and AOPP and in the urinary levels of 8-OHdG
in T2DM patients compared to healthy controls; similar results
were observed inT2DMpatients withmicro-andmacrovascular
complications in comparison to those without complications.
These studies present some limitations that should be
addressed in future research: in particular, neither potential
gender-related differences nor racial disparities in oxidative
stress biomarkers have been actively investigated so far; nev-
ertheless, both racial and gender differences in the markers of
oxidative stress have been reported [68, 112, 113]. A
limitation of many studies is that medications such as statins,
β-blockers, angiotensin-converting enzyme inhibitors, and
angiotensin receptor blockers which exhibit antioxidant
effects were not always analysed as potential confounding
factors [114]; a limitation of many studies is that these med-
ications were not always included in the analyses as potential
confounding factors.
From an overall point of view, despite the heterogeneity of
T2DMpatients in termsof stage anddurationand thepresence
of different complications, what emerges from retrospective
human studies is that there is an associationbetween increased
circulating oxidative damage biomarkers, T2DM, and its com-
plications. Nevertheless, none of these biomarkers has never
reached clinical practice mainly because of the lack of stan-
dardized methods and reference range intervals and the lack
of validation in prospective trials. In fact, in spite of the prom-
ising results from observational clinical studies, a recent large
prospective study concluded that none of the different bio-
markers of oxidative stress used (AGE, AOPP, protein car-
bonyls, and antioxidant capacity of plasma) was associated
with adverse cardiovascular events [80]. However, encourag-
ing results were obtained with the nucleic acid oxidation bio-
markers, 8-oxoGuo and 8-OHdG measured in the urines,
Table 2: Continued.
Disease and population Sample Markers Observation
Information on medication or
supplements
Reference
Controls (N = 171)
Ethnicity: Indians
↑AGE in T2DMwith complications
compared to those without
8-iso-PGF2α: 8-iso- prostaglandin F2α ; 8-OHdG: 8-hydroxy-2′-deoxyguanosine; 8-oxoGuo: 8-oxo-7,8-dihydroguanosine; AGEs: advanced glycation end
products; AOPP: advanced oxidation protein products ;CAT: catalase; FRAP: ferric reducing ability of plasma; GSH: reduced glutathione; GSSG: oxidized
glutathione; GPx: glutathione peroxidase; GR: glutathione reductase; HNE: 4-hydroxy-2-nonenal; HO1: heme oxygenase; MDA: malondialdehyde; PON1:
paraoxonase 1; SOD: superoxide dismutase; TBARS: thiobarbituric acid reactive substances; TAS: total antioxidant status.
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whichmaybeuseful topredictmicro-andmacrovascular com-
plications ofT2DM.Data referring to antioxidant defence sys-
tems are more inconclusive since they have been found either
decreased or increased. Emerging evidence also points out
the relationship between serum PON1 and HO1 in T2DM
and its complications, and a recent meta-analysis demon-
strated thatPON1was significantly associatedwith the suscep-
tibility of T2DM and to the development of macro- and
microangiopathy [115].
From a mechanistic point of view, even if oxidative stress
is involved in nearly all stages of micro- and macrovascular
disease development [116–118], the relative importance of
each biomarker of oxidative nucleic, protein, or lipid damage
and whether one may be related to a greater extent with the
key mechanisms of T2DM and its complications need further
investigations (Figure 2).
The evaluation of oxidative damage biomarkers may be
also relevant for better phenotyping patients; Seddon et al.
Table 3: Selected clinical prospective studies on circulating oxidative stress markers in T2DM. Categories are based on the following evidence
levels: (A) large prospective studies and (B) prospective studies.
Disease and
population
Sample Markers Observation
Class of
evidence
Information on medication or
supplements
Reference
T2DM
(N = 1468) Plasma
AOPP
AGE
Protein
carbonyl
Total
reductive
capacity of
plasma
AOPP and total
reductive capacity of plasma were not
associated with the risk of major adverse
cardiovascular events
↑ AGE and carbonyls were associated with
the risk of major adverse cardiovascular
events in univariate analysis but not in
multivariate analysis
A
Use of statins included in the
multivariate model
[80]
T2DM
(N = 3766) Urine 8-OHdG
↑ 8-OHdG is independently associated with
all-cause mortality and cardiovascular
mortality
A
Use of aspirin, statins, beta
blockers, and ACE inhibitors/ARB
included in statistical analysis
[95]
T2DM
(N = 411) Plasma AGEs
Baseline AGEs associated with subclinical
atherosclerosis parameters over 10 years of
follow-up
B No clear indication [78]
T2DM
(N = 1900) Urine
8-oxoGuo
8-OHdG
8-oxoGuo was associated with all-cause
mortality and cardiovascular death
8-OHdG was not
associated with survival
A
No clear indication whether drugs
were included in statistical analysis
[96]
T2DM
(N = 1381) Urine 8-oxoGuo
8-oxoGuo was associated with all-cause
mortality and CVD at diagnosis and
at 6-year follow-up
A No clear indication [97]
Newly
diagnosed
T2DM
(N = 1381)
Urine
8-oxoGuo
8-OHdG
8-oxoGuo at diagnosis predicted all-cause
and diabetes-related mortality over 6 years
8-OHdG was not associated with survival
A No clear indication [94]
T2DM
(N = 716) Plasma AGEs
AGEs were associated with incident
cardiovascular events over 3–7 years of
follow-up
B No clear indication [79]
T2DM
(N = 1412) Plasma
AGEs
Protein
carbonyls
No independent associations between
lower-extremity artery disease and AGE or
protein carbonyls
A
Use of insulin therapy and
antihypertensive,statin, fibrate, and
antiplatelet drugs included in
statistical analysis
[81]
T2DM
(N = 108) Serum PON1
Lower PON1 activity and concentration
were associated with an increased risk of
developing cardiovascular disease
B Not provided [107]
(N = 234)
with no
preexisting
diabetes
Serum PON1
Lower PON1 activity and concentration
were associated with an increased risk of
developing T2DM
B Not provided [108]
(N = 5947)
with no
preexisting
diabetes
Serum PON1
Incident T2DM was not associated with
PON1
A Not provided [109]
8-OHdG: 8-hydroxy-2′-deoxyguanosine; 8-oxoGuo: 8-oxo-7,8-dihydroguanosine; AGEs: advanced glycation end products; AOPP: advanced oxidation protein
products; IMA: ischemia-modified albumin; PON1: paraoxonase 1.
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[116] highlighted that oxidative stress is a redox disease and a
potential covariate in predicting patient recovery on an
antidiabetic treatment; this highlights the need to identify
those patients who are likely to need specific pharmaco-
logical strategies that can target oxidative stress, beyond
lowering glucose.
Moreover, several drugs used for the treatment of T2DM
have been shown to exert pleiotropic effects [117] but, to
date, the relationship between glycaemic control, oxidative
stress, and endogenous antioxidant defence systems has
received limited attention in clinical studies.
In particular, it is the case of the newer glucose-lowering
drugs such as GLP-1 analogues, dipeptidyl peptidase 4
(DPP4) inhibitors, and sodium-glucose cotransporter 2
inhibitors (SGLT2i). Interestingly, a recent large study dem-
onstrated that GLP-1 analogues, beyond improving glycae-
mic control and promoting weight loss, improve
cardiovascular outcomes in patients at high cardiovascular
risk [118], and this effect was associated with reduced oxida-
tive stress [119].
10. Conclusions
There is a need to improve our knowledge about T2DM
and its complications in order to be able to develop new
targets of intervention. Oxidative stress represents one of
the mechanisms involved in the pathogenesis and progres-
sion of T2DM and its complications, suggesting that it
may be considered as an additional target for pharmaco-
therapy. In this view, the measurement of the circulating
biomarkers of oxidative stress offers several advantages
including easy collection, low cost, and the possibility of
use in large clinical studies. At present, among several bio-
markers, urinary 8-OHdG and 8-oxoGuo, serum PON1
and HO1 seem to be the most promising for predicting
cardiovascular disease in T2DM.
However, the measurement of oxidative stress bio-
markers may have several other clinical applications such as
patient selection and stratification as well as monitoring the
clinical efficacy of medications supposed to affect oxidative
stress. Direction for future research should also include fur-
ther mechanistic studies linking each biomarker to disease
onset and progression including their temporal variations
from the early to the late stages of the disease.
By better targeting the mechanisms involved in disease
pathogenesis and progression, with old or new therapeutic
strategies, we can expect to improve the outcomes of
T2DM patients. Therefore, the measurement of oxidative
stress biomarkers in clinical trials deserves to be considered
as an additional tool to currently used parameters to facilitate
a more individualized treatment of T2DM in terms of drug
choice and patient selection.
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